A working group formed by the European Group for Blood and Marrow Transplantation (EBMT) and European LeukemiaNet has developed recommendations for prophylaxis and treatment of acute and chronic GVHD. The four-part recommendations cover prevention of GVHD in standard myeloablative transplantation, prevention of GVHD in reduced-intensity transplantation, treatment of acute GVHD, and treatment of chronic GVHD. The group's report recommends that the guidelines be adopted as standards in transplant centers and used as a standard of care in studies evaluating the advantages and disadvantages of practices differing from the recommendations.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Report: Prophylaxis and Treatment of GVHD
Aug 2013